Skip to main content
Top
Published in: AIDS Research and Therapy 1/2010

Open Access 01-12-2010 | Research

A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences

Authors: Kim Steegen, Michelle Bronze, Elke Van Craenenbroeck, Bart Winters, Koen Van der Borght, Carole L Wallis, Wendy Stevens, Tobias F Rinke de Wit, Lieven J Stuyver, the ART-A consortium

Published in: AIDS Research and Therapy | Issue 1/2010

Login to get access

Abstract

Background

As second-line antiretroviral treatment (ART) becomes more accessible in resource-limited settings (RLS), the need for more affordable monitoring tools such as point-of-care viral load assays and simplified genotypic HIV drug resistance (HIVDR) tests increases substantially. The prohibitive expenses of genotypic HIVDR assays could partly be addressed by focusing on a smaller region of the HIV reverse transcriptase gene (RT) that encompasses the majority of HIVDR mutations for people on ART in RLS. In this study, an in silico analysis of 125,329 RT sequences was performed to investigate the effect of submitting short RT sequences (codon 41 to 238) to the commonly used virco®TYPE and Stanford genotype interpretation tools.

Results

Pair-wise comparisons between full-length and short RT sequences were performed. Additionally, a non-inferiority approach with a concordance limit of 95% and two-sided 95% confidence intervals was used to demonstrate concordance between HIVDR calls based on full-length and short RT sequences.
The results of this analysis showed that HIVDR interpretations based on full-length versus short RT sequences, using the Stanford algorithms, had concordance significantly above 95%. When using the virco®TYPE algorithm, similar concordance was demonstrated (>95%), but some differences were observed for d4T, AZT and TDF, where predictions were affected in more than 5% of the sequences. Most differences in interpretation, however, were due to shifts from fully susceptible to reduced susceptibility (d4T) or from reduced response to minimal response (AZT, TDF) or vice versa, as compared to the predicted full RT sequence. The virco®TYPE prediction uses many more mutations outside the RT 41-238 amino acid domain, which significantly contribute to the HIVDR prediction for these 3 antiretroviral agents.

Conclusions

This study illustrates the acceptability of using a shortened RT sequences (codon 41-238) to obtain reliable genotype interpretations by virco®TYPE and Stanford algorithms. Implementation of this simplified protocol could significantly reduce the cost of both resistance testing and ARV treatment monitoring in RLS.
Appendix
Available only for authorised users
Literature
1.
go back to reference DHHS: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2008, DHHS: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2008,
2.
go back to reference EACS: Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2008. 2008, EACS: Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2008. 2008,
3.
go back to reference WHO: Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach. 2006, Geneva: World Health Organization, WHO: Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach. 2006, Geneva: World Health Organization,
4.
go back to reference WHO: New WHO Recommendations: Antiretroviral therapy for adults and adolescents. Geneva: WHO,2009 WHO: New WHO Recommendations: Antiretroviral therapy for adults and adolescents. Geneva: WHO,2009
5.
go back to reference WHO: Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003, Geneva: World Health Organization, WHO: Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003, Geneva: World Health Organization,
6.
go back to reference WHO/UNAIDS/UNICEF: Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. 2009, Geneva: WHO, WHO/UNAIDS/UNICEF: Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. 2009, Geneva: WHO,
7.
go back to reference Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K: Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007, 11: 413-416. 10.1016/j.ijid.2006.11.003CrossRefPubMed Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K: Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007, 11: 413-416. 10.1016/j.ijid.2006.11.003CrossRefPubMed
8.
go back to reference Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009, 23: 1127-1134. 10.1097/QAD.0b013e32832ac34ePubMedCentralCrossRefPubMed Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009, 23: 1127-1134. 10.1097/QAD.0b013e32832ac34ePubMedCentralCrossRefPubMed
9.
go back to reference Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008, 22: 1971-1977. 10.1097/QAD.0b013e32830e4cd8CrossRefPubMed Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008, 22: 1971-1977. 10.1097/QAD.0b013e32830e4cd8CrossRefPubMed
10.
go back to reference Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J: CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008, 49: 477-484. 10.1097/QAI.0b013e318186eb18CrossRefPubMed Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J: CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008, 49: 477-484. 10.1097/QAI.0b013e318186eb18CrossRefPubMed
11.
go back to reference Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I: Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009, 23: 697-700. 10.1097/QAD.0b013e3283262a78PubMedCentralCrossRefPubMed Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I: Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009, 23: 697-700. 10.1097/QAD.0b013e3283262a78PubMedCentralCrossRefPubMed
13.
go back to reference Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D: Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009, 17: 138-145.PubMed Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D: Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009, 17: 138-145.PubMed
14.
go back to reference Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010, 10: 155-166. 10.1016/S1473-3099(09)70328-7CrossRefPubMed Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010, 10: 155-166. 10.1016/S1473-3099(09)70328-7CrossRefPubMed
15.
go back to reference Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008, 46: 1589-1597. 10.1086/587109PubMedCentralCrossRefPubMed Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008, 46: 1589-1597. 10.1086/587109PubMedCentralCrossRefPubMed
16.
go back to reference Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R: HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009, 14: 523-531.PubMedCentralPubMed Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R: HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009, 14: 523-531.PubMedCentralPubMed
17.
go back to reference Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W: Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010, 53: 480-484. 10.1097/QAI.0b013e3181bc478bCrossRefPubMed Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W: Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010, 53: 480-484. 10.1097/QAI.0b013e3181bc478bCrossRefPubMed
18.
go back to reference Steegen K, Bronze M, Van Craenenbroeck E, Stevens W, Rinke de Wit TF, Stuyver LJ: An affordable genotypic HIV drug resistance protocol for truncated reverse transcriptase compatible to the vircoTYPE prediction tool (O_4). 3rd International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings. 2009, Lusaka, Zambia, Steegen K, Bronze M, Van Craenenbroeck E, Stevens W, Rinke de Wit TF, Stuyver LJ: An affordable genotypic HIV drug resistance protocol for truncated reverse transcriptase compatible to the vircoTYPE prediction tool (O_4). 3rd International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings. 2009, Lusaka, Zambia,
19.
go back to reference Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P: Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007, 145: 47-55. 10.1016/j.jviromet.2007.05.009CrossRefPubMed Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P: Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007, 145: 47-55. 10.1016/j.jviromet.2007.05.009CrossRefPubMed
20.
go back to reference Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L: Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods. 2009, 162: 101-108. 10.1016/j.jviromet.2009.07.023CrossRefPubMed Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L: Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods. 2009, 162: 101-108. 10.1016/j.jviromet.2009.07.023CrossRefPubMed
21.
go back to reference Verlinden Y, Vermeiren H, Lecocq P, Bacheler L, McKenna P, Vanpachtenbeke M: Assessment of the Antivirogram® performance over time including a revised definition of biological test cut-off values. XIVth International HIV Drug Resistance Workshop. 2005, Québec City, Québec, Canada, Verlinden Y, Vermeiren H, Lecocq P, Bacheler L, McKenna P, Vanpachtenbeke M: Assessment of the Antivirogram® performance over time including a revised definition of biological test cut-off values. XIVth International HIV Drug Resistance Workshop. 2005, Québec City, Québec, Canada,
Metadata
Title
A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences
Authors
Kim Steegen
Michelle Bronze
Elke Van Craenenbroeck
Bart Winters
Koen Van der Borght
Carole L Wallis
Wendy Stevens
Tobias F Rinke de Wit
Lieven J Stuyver
the ART-A consortium
Publication date
01-12-2010
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2010
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-7-38

Other articles of this Issue 1/2010

AIDS Research and Therapy 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.